MARK G FOLETTA Insider Trading Transactions
Get free email notifications about insider trading for MARK G FOLETTA.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of MARK G FOLETTA. MARK G FOLETTA is Senior VP, Finance & CFO in AMYLIN PHARMACEUTICALS INC ($AMLN) and Sr VP Finance & CFO in AMYLIN PHARMACEUTICALS INC ($AMLN) and SVP Chief Financial Officer in AMYLIN PHARMACEUTICALS INC ($AMLN) and SVP, Chief Financial Officer in AMYLIN PHARMACEUTICALS INC ($AMLN) and VP & Chief Financial Officer in AMYLIN PHARMACEUTICALS INC ($AMLN) and VP Finance & CFO in AMYLIN PHARMACEUTICALS INC ($AMLN) and Director in AMN HEALTHCARE SERVICES INC ($AHS) and Director in DEXCOM INC ($DXCM) and Director in ENANTA PHARMACEUTICALS INC ($ENTA) and Interim CFO in BIOCEPT INC ($BIOC) and EVP & Chief Financial Officer in Tocagen Inc ($TOCA) and Director in Regulus Therapeutics Inc. ($RGLS).
Latest Insider Trading Transactions of MARK G FOLETTA
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AHS, AMLN, BIOC, DXCM, ENTA, TOCA, RGLS
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 23 2021 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Option Exercise | A | 0.00 | 2,139 | 0 | 2,139 | |
Apr 23 2021 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Option Exercise | M | 0.00 | 2,826 | 0 | 0 | |
Apr 23 2021 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Buy | M | 0.00 | 2,826 | 0 | 14,776 | 12 K to 14.8 K (+23.65 %) |
Mar 04 2021 | ENTA | ENANTA PHARMACEUTI ... | FOLETTA MARK G | Director | Option Exercise | A | 49.92 | 7,500 | 374,400 | 7,500 | |
Oct 19 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 398.25 | 208 | 82,835 | 14,202 | 14.4 K to 14.2 K (-1.44 %) |
Oct 19 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 397.41 | 375 | 149,030 | 14,410 | 14.8 K to 14.4 K (-2.54 %) |
Oct 19 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 396.51 | 255 | 101,109 | 14,785 | 15 K to 14.8 K (-1.70 %) |
Oct 19 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 395.02 | 120 | 47,402 | 15,040 | 15.2 K to 15 K (-0.79 %) |
Oct 19 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 391.48 | 42 | 16,442 | 15,160 | 15.2 K to 15.2 K (-0.28 %) |
Sep 16 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 397.75 | 114 | 45,344 | 15,202 | 15.3 K to 15.2 K (-0.74 %) |
Sep 16 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 397.75 | 114 | 45,344 | 15,202 | 15.3 K to 15.2 K (-0.74 %) |
Sep 16 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 396.17 | 121 | 47,936 | 15,316 | 15.4 K to 15.3 K (-0.78 %) |
Sep 16 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 396.17 | 121 | 47,936 | 15,316 | 15.4 K to 15.3 K (-0.78 %) |
Sep 16 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 395.28 | 222 | 87,753 | 15,437 | 15.7 K to 15.4 K (-1.42 %) |
Sep 16 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 395.28 | 222 | 87,753 | 15,437 | 15.7 K to 15.4 K (-1.42 %) |
Sep 16 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 393.73 | 231 | 90,951 | 15,659 | 15.9 K to 15.7 K (-1.45 %) |
Sep 16 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 393.73 | 231 | 90,951 | 15,659 | 15.9 K to 15.7 K (-1.45 %) |
Sep 16 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 391.95 | 200 | 78,390 | 15,890 | 16.1 K to 15.9 K (-1.24 %) |
Sep 16 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 391.95 | 200 | 78,390 | 15,890 | 16.1 K to 15.9 K (-1.24 %) |
Sep 16 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 390.86 | 109 | 42,604 | 16,090 | 16.2 K to 16.1 K (-0.67 %) |
Sep 16 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 390.86 | 109 | 42,604 | 16,090 | 16.2 K to 16.1 K (-0.67 %) |
Sep 16 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 386.21 | 3 | 1,159 | 16,199 | 16.2 K to 16.2 K (-0.02 %) |
Sep 16 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 386.21 | 3 | 1,159 | 16,199 | 16.2 K to 16.2 K (-0.02 %) |
Jul 01 2020 | ENTA | ENANTA PHARMACEUTI ... | FOLETTA MARK G | Director | Option Exercise | A | 49.04 | 17,000 | 833,680 | 17,000 | |
May 27 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Buy | J | 0.00 | 3,055 | 0 | 16,202 | 13.1 K to 16.2 K (+23.24 %) |
May 27 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Grant | A | 0.00 | 895 | 1 | 895 | 0 to 895 |
May 27 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | J | 0.00 | 3,055 | 0 | 0 | 3.1 K to 0 (-100.00 %) |
Apr 24 2020 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Option Exercise | A | 0.00 | 2,826 | 0 | 2,826 | |
Apr 21 2020 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Option Exercise | M | 0.00 | 2,907 | 0 | 0 | |
Apr 21 2020 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Buy | M | 0.00 | 2,907 | 0 | 11,950 | 9 K to 12 K (+32.15 %) |
Mar 04 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 288.26 | 84 | 24,214 | 13,147 | 13.2 K to 13.1 K (-0.63 %) |
Mar 04 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 285.48 | 75 | 21,411 | 13,231 | 13.3 K to 13.2 K (-0.56 %) |
Mar 04 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 282.77 | 84 | 23,753 | 13,306 | 13.4 K to 13.3 K (-0.63 %) |
Mar 04 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 281.61 | 53 | 14,925 | 13,390 | 13.4 K to 13.4 K (-0.39 %) |
Mar 04 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 279.60 | 31 | 8,668 | 13,443 | 13.5 K to 13.4 K (-0.23 %) |
Mar 04 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 277.48 | 64 | 17,759 | 13,474 | 13.5 K to 13.5 K (-0.47 %) |
Mar 04 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 275.56 | 114 | 31,414 | 13,538 | 13.7 K to 13.5 K (-0.84 %) |
Mar 04 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 274.88 | 155 | 42,607 | 13,652 | 13.8 K to 13.7 K (-1.12 %) |
Mar 04 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 272.82 | 81 | 22,098 | 13,807 | 13.9 K to 13.8 K (-0.58 %) |
Mar 04 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 271.54 | 152 | 41,274 | 13,888 | 14 K to 13.9 K (-1.08 %) |
Mar 04 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 270.63 | 107 | 28,957 | 14,040 | 14.1 K to 14 K (-0.76 %) |
Feb 05 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 240.68 | 9 | 2,166 | 14,147 | 14.2 K to 14.1 K (-0.06 %) |
Feb 05 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 238.86 | 166 | 39,650 | 14,156 | 14.3 K to 14.2 K (-1.16 %) |
Feb 05 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 238.05 | 524 | 124,736 | 14,322 | 14.8 K to 14.3 K (-3.53 %) |
Feb 05 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 236.85 | 301 | 71,290 | 14,846 | 15.1 K to 14.8 K (-1.99 %) |
Jan 07 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 218.94 | 133 | 29,118 | 15,147 | 15.3 K to 15.1 K (-0.87 %) |
Jan 07 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 218.39 | 339 | 74,035 | 15,280 | 15.6 K to 15.3 K (-2.17 %) |
Jan 07 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 217.61 | 528 | 114,899 | 15,619 | 16.1 K to 15.6 K (-3.27 %) |
Jan 07 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 218.94 | 133 | 29,118 | 15,147 | 15.3 K to 15.1 K (-0.87 %) |
Jan 07 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 218.39 | 339 | 74,035 | 15,280 | 15.6 K to 15.3 K (-2.17 %) |
Jan 07 2020 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 217.61 | 528 | 114,899 | 15,619 | 16.1 K to 15.6 K (-3.27 %) |
Dec 05 2019 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 228.93 | 462 | 105,766 | 16,147 | 16.6 K to 16.1 K (-2.78 %) |
Dec 05 2019 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 227.66 | 233 | 53,046 | 16,609 | 16.8 K to 16.6 K (-1.38 %) |
Dec 05 2019 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 226.20 | 232 | 52,478 | 16,842 | 17.1 K to 16.8 K (-1.36 %) |
Dec 05 2019 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 223.41 | 70 | 15,639 | 17,074 | 17.1 K to 17.1 K (-0.41 %) |
Dec 05 2019 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 221.34 | 3 | 664 | 17,144 | 17.1 K to 17.1 K (-0.02 %) |
Oct 04 2019 | TOCA | Tocagen Inc | FOLETTA MARK G | EVP & Chief Financi ... | Option Exercise | A | 0.64 | 30,000 | 19,173 | 30,000 | |
Oct 04 2019 | TOCA | Tocagen Inc | FOLETTA MARK G | EVP & Chief Financi ... | Option Exercise | A | 0.64 | 30,000 | 19,173 | 30,000 | |
Jun 04 2019 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Grant | A | 0.00 | 3,055 | 3 | 3,055 | 0 to 3.1 K |
Jun 04 2019 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Buy | J | 0.00 | 4,052 | 0 | 17,147 | 13.1 K to 17.1 K (+30.94 %) |
Jun 04 2019 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | J | 0.00 | 4,052 | 0 | 0 | 4.1 K to 0 (-100.00 %) |
May 29 2019 | TOCA | Tocagen Inc | FOLETTA MARK G | EVP & Chief Financi ... | Buy | P | 4.30 | 5,000 | 21,475 | 15,042 | 10 K to 15 K (+49.79 %) |
May 17 2019 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 122.73 | 400 | 49,091 | 13,095 | 13.5 K to 13.1 K (-2.96 %) |
May 17 2019 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 121.88 | 500 | 60,939 | 13,495 | 14 K to 13.5 K (-3.57 %) |
May 17 2019 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 118.65 | 100 | 11,865 | 13,995 | 14.1 K to 14 K (-0.71 %) |
Apr 19 2019 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Option Exercise | A | 0.00 | 2,907 | 0 | 2,907 | |
Apr 19 2019 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Option Exercise | M | 0.00 | 2,153 | 0 | 0 | |
Apr 19 2019 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Buy | M | 0.00 | 2,153 | 0 | 9,043 | 6.9 K to 9 K (+31.25 %) |
Apr 17 2019 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 119.36 | 599 | 71,497 | 14,095 | 14.7 K to 14.1 K (-4.08 %) |
Apr 17 2019 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 118.88 | 301 | 35,784 | 14,694 | 15 K to 14.7 K (-2.01 %) |
Apr 17 2019 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 116.96 | 100 | 11,696 | 14,995 | 15.1 K to 15 K (-0.66 %) |
Mar 19 2019 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 151.97 | 100 | 15,197 | 15,095 | 15.2 K to 15.1 K (-0.66 %) |
Mar 19 2019 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 151.00 | 700 | 105,698 | 15,195 | 15.9 K to 15.2 K (-4.40 %) |
Mar 19 2019 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 146.92 | 200 | 29,384 | 15,895 | 16.1 K to 15.9 K (-1.24 %) |
Feb 20 2019 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 149.52 | 200 | 29,904 | 16,095 | 16.3 K to 16.1 K (-1.23 %) |
Feb 20 2019 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 148.52 | 800 | 118,819 | 16,295 | 17.1 K to 16.3 K (-4.68 %) |
Aug 28 2018 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 137.50 | 1,000 | 137,503 | 17,095 | 18.1 K to 17.1 K (-5.53 %) |
Jun 04 2018 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Grant | A | 0.00 | 4,062 | 4 | 9,014 | 5 K to 9 K (+82.03 %) |
Apr 20 2018 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Option Exercise | M | 0.00 | 3,365 | 0 | 0 | |
Apr 20 2018 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Option Exercise | A | 0.00 | 2,153 | 0 | 0 | |
Apr 20 2018 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Buy | M | 0.00 | 3,365 | 0 | 6,890 | 3.5 K to 6.9 K (+95.46 %) |
Mar 02 2018 | TOCA | Tocagen Inc | FOLETTA MARK G | EVP & Chief Financi ... | Option Exercise | A | 11.19 | 85,000 | 951,150 | 85,000 | |
Dec 14 2017 | TOCA | Tocagen Inc | FOLETTA MARK G | EVP & Chief Financi ... | Buy | J | 8.50 | 2,500 | 21,250 | 7,500 | 5 K to 7.5 K (+50.00 %) |
Dec 06 2017 | RGLS | Regulus Therapeuti ... | FOLETTA MARK G | Director | Grant | A | 0.89 | 71,910 | 64,000 | 81,910 | 10 K to 81.9 K (+719.10 %) |
Nov 29 2017 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 54.95 | 2,500 | 137,386 | 13,143 | 15.6 K to 13.1 K (-15.98 %) |
Nov 28 2017 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Sell | S | 47.03 | 2,500 | 117,575 | 3,525 | 6 K to 3.5 K (-41.49 %) |
Jun 14 2017 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Sell | S | 36.71 | 1,500 | 55,058 | 6,025 | 7.5 K to 6 K (-19.93 %) |
Jun 05 2017 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Grant | A | 0.00 | 4,952 | 5 | 20,595 | 15.6 K to 20.6 K (+31.66 %) |
Jun 02 2017 | RGLS | Regulus Therapeuti ... | FOLETTA MARK G | Director | Option Exercise | A | 1.45 | 30,000 | 43,500 | 30,000 | |
May 31 2017 | TOCA | Tocagen Inc | FOLETTA MARK G | EVP & Chief Financi ... | Option Exercise | A | 16.32 | 85,000 | 1,387,200 | 85,000 | |
Apr 21 2017 | TOCA | Tocagen Inc | FOLETTA MARK G | EVP & Chief Financi ... | Buy | P | 10.00 | 5,000 | 50,000 | 5,000 | 0 to 5 K |
Apr 20 2017 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Option Exercise | M | 0.00 | 3,793 | 0 | 0 | |
Apr 20 2017 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Option Exercise | A | 0.00 | 3,365 | 0 | 3,365 | |
Apr 20 2017 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Buy | M | 0.00 | 3,793 | 0 | 7,525 | 3.7 K to 7.5 K (+101.63 %) |
Dec 16 2016 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Sell | S | 37.81 | 1,800 | 68,058 | 3,732 | 5.5 K to 3.7 K (-32.54 %) |
Sep 09 2016 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Sell | S | 94.63 | 1,800 | 170,325 | 15,643 | 17.4 K to 15.6 K (-10.32 %) |
Jun 03 2016 | RGLS | Regulus Therapeuti ... | FOLETTA MARK G | Director | Option Exercise | A | 6.20 | 36,620 | 227,044 | 36,620 | |
May 26 2016 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Grant | A | 0.00 | 5,450 | 5 | 17,443 | 12 K to 17.4 K (+45.44 %) |
Apr 22 2016 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Option Exercise | A | 0.00 | 3,793 | 0 | 3,793 | |
Apr 22 2016 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Option Exercise | M | 0.00 | 5,532 | 0 | 0 | |
Apr 22 2016 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Buy | M | 0.00 | 5,532 | 0 | 5,532 | 0 to 5.5 K |
Sep 02 2015 | BIOC | BIOCEPT INC | FOLETTA MARK G | Interim CFO | Option Exercise | A | 2.01 | 50,000 | 100,500 | 50,000 | |
Aug 13 2015 | RGLS | Regulus Therapeuti ... | FOLETTA MARK G | Director | Buy | P | 7.64 | 10,000 | 76,405 | 10,000 | 0 to 10 K |
Jun 26 2015 | RGLS | Regulus Therapeuti ... | FOLETTA MARK G | Director | Option Exercise | A | 10.02 | 17,500 | 175,350 | 17,500 | |
Jun 05 2015 | DXCM | DEXCOM INC | FOLETTA MARK G | Director | Grant | A | 0.00 | 4,671 | 5 | 11,993 | 7.3 K to 12 K (+63.79 %) |
Apr 24 2015 | AHS | AMN HEALTHCARE SER ... | FOLETTA MARK G | Director | Option Exercise | A | 0.00 | 5,532 | 0 | 5,532 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | J | 0.00 | 40,000 | 0 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | H | 41.34 | 46,799 | 1,934,671 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | H | 36.90 | 67,289 | 2,482,964 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | J | 24.87 | 65,980 | 1,640,923 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | J | 22.60 | 34,884 | 788,378 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | J | 18.85 | 23,722 | 447,160 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | J | 18.01 | 44,243 | 796,816 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | J | 16.54 | 35,475 | 586,757 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | J | 16.02 | 112,207 | 1,797,556 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | J | 15.03 | 70,843 | 1,064,770 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | J | 9.02 | 56,248 | 507,357 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | H | 41.34 | 3,201 | 132,329 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | H | 36.90 | 2,711 | 100,036 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | J | 24.87 | 4,020 | 99,977 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | J | 22.60 | 5,116 | 115,622 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | J | 18.85 | 8,361 | 157,605 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | J | 18.01 | 5,757 | 103,684 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | J | 16.54 | 4,525 | 74,844 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | J | 16.02 | 7,793 | 124,844 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | J | 15.03 | 9,157 | 137,630 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | J | 9.02 | 3,752 | 33,843 | 0 | |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Sell | U | 31.00 | 110 | 3,410 | 0 | 110 to 0 (-100.00 %) |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Sell | U | 31.00 | 2,889 | 89,559 | 0 | 2.9 K to 0 (-100.00 %) |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Sell | U | 31.00 | 5,085 | 157,635 | 2,889 | 8 K to 2.9 K (-63.77 %) |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Sell | U | 31.00 | 3,415 | 105,865 | 0 | 3.4 K to 0 (-100.00 %) |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Sell | U | 31.00 | 453 | 14,043 | 3,415 | 3.9 K to 3.4 K (-11.71 %) |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Sell | J | 31.00 | 64,702 | 2,005,762 | 0 | 64.7 K to 0 (-100.00 %) |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Sell | U | 31.00 | 65,115 | 2,018,565 | 64,702 | 129.8 K to 64.7 K (-50.16 %) |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Sell | U | 31.00 | 8,255 | 255,905 | 129,817 | 138.1 K to 129.8 K (-5.98 %) |
Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Buy | J | 31.00 | 64,702 | 2,005,762 | 138,072 | 73.4 K to 138.1 K (+88.19 %) |
Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Grant | A | 14.62 | 880 | 12,866 | 73,370 | 72.5 K to 73.4 K (+1.21 %) |
Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | A | 16.02 | 112,207 | 1,797,556 | 112,207 | |
Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | A | 16.02 | 7,793 | 124,844 | 7,793 | |
Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Grant | A | 0.00 | 1,529 | 0 | 7,974 | 6.4 K to 8 K (+23.72 %) |
Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Grant | A | 0.00 | 10,000 | 0 | 72,490 | 62.5 K to 72.5 K (+16.00 %) |
Mar 02 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Sell | S | 17.11 | 1,846 | 31,585 | 62,490 | 64.3 K to 62.5 K (-2.87 %) |
Feb 24 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Sell | S | 17.03 | 5,638 | 96,016 | 63,439 | 69.1 K to 63.4 K (-8.16 %) |
Feb 24 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Grant | A | 0.00 | 15,000 | 0 | 69,077 | 54.1 K to 69.1 K (+27.74 %) |
Feb 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Payment of Exercise | F | 16.47 | 3,122 | 51,419 | 54,565 | 57.7 K to 54.6 K (-5.41 %) |
Feb 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Grant | A | 0.00 | 8,000 | 0 | 57,687 | 49.7 K to 57.7 K (+16.10 %) |
Jan 12 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Grant | A | 0.00 | 7,500 | 0 | 49,687 | 42.2 K to 49.7 K (+17.78 %) |
Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | A | 15.03 | 70,843 | 1,064,770 | 70,843 | |
Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | A | 15.03 | 9,157 | 137,630 | 9,157 | |
Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Grant | A | 0.00 | 1,630 | 0 | 6,445 | 4.8 K to 6.4 K (+33.85 %) |